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OBJECTIVES: In the UK, access to anti-TNF therapies for the treatment of rheuma-
toid arthritis (RA) is standardized by National Institute for Clinical Excellence guid-
ance. Certolizumab pegol (CZP) studies in RA demonstrate that patient response to
therapy at 12 weeks predicts clinical outcome at 1 year. In the UK, CZP is available
via a Patient Access Scheme (PAS), providing CZP free for the first 12 weeks. This
analysis examines persistency and potential cost savings realised with a 12 week
CZP decision. METHODS: A retrospective analysis examined 2,744 patients receiv-
ing CZP between March 2010 and March 2012 from Healthcare at Home, a UK home
health care service provider. Persistence was defined as patients (%) continuing to
receive CZP deliveries, calculated at specific time points. Treatment start was first
delivery date and patients were censored according to this. A simple cost analysis
was performed. RESULTS: At 13, 26, 39 and 52 weeks, persistence rates were 93%,
79%, 70% and 65% in naive (no prior anti-TNF) and 88%, 68%, 56% and 48% in switch
(1 prior anti-TNF) patients respectively. Analyzing first-line biologic drug costs
only, the NHS would save £2,363.14/patient in the first year if CZP were used instead
of adalimumab (assuming similar persistence); largely due to the PAS. Stopping
treatment for non-responders at Week 12 (CZP) vs Week 24 (adalimumab), could
allow the UK NHS to re-invest £ 2145/patient. CONCLUSIONS: In this UK cohort,
CZP persistence was higher in naive pts. Reinforcing a 12 week treatment decision
could result in more efficient spend on drugs and rapid initiation of alternative
treatment in non-responders.
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OBJECTIVES: To estimate the budget impact of PP-LAI in treating chronic schizo-
phrenia in Brazil from the perspective of the public payer, specifically for patients
with adherence issues. METHODS: The budget impact model (BIM) was used to
estimate eligible population and to project investments for the first 5y (2012-2016).
An approach based on prevalence and adherence rates reported by previous stud-
ies was employed to define the eligible population. Two scenarios were simulated:
1) the current setting, in which schizophrenic patients with adherence issues re-
ceive atypical drugs already provided by the Brazilian Public Healthcare System
(BPHS) (olanzapine, quetiapine and ziprasidone), and 2) the proposed setting, in
which patients presenting non-adherence behaviors on oral atypical therapy can
receive PP-LAI. Final costs were calculated considering drug acquisition costs and
health resource consumption related to outpatient follow-up, hospitalizations and
adverse events. RESULTS: The BIM estimated the population eligible for PP-LAI
ranging from 2,207 patients (2012) to 2,271 patients (2016), approximately 0.3% of
the projected schizophrenia population attending BPHS services. With all drugs tax
exempted, the acquisition costs were: PP-LAI 5,566BRL (1st year) and 4,963BRL (sub-
sequent years); olanzapine 3,850BRL; quetiapine 5,416BRL; ziprasidone 1,474BRL.
The model estimated the current BPHS expenses at 287 million BRL in 2012, reach-
ing 296 million BRL in 2016. If PP-LAI is included in the reimbursement list, the
yearly budget impact in 2012 would be 2.4 million (0.83%) and 1.1 million in 2016
(0.37%). The cumulative budget impact would reach 6,658,573BRL in 5 years.
CONCLUSIONS: PP-LAI is an effective therapeutic option for schizophrenic pa-
tients, particularly those who would benefit from LAI antipsychotic drugs. In this
BIM, the investments to include PP-LAI on BPHS reimbursement lists were esti-
mated to be BRL 6.7 million in five years (an increment of 0.46% in the current
budget).
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OBJECTIVES:To examine the influence of intranasal corticosteroid (INS) adherence
on 18-month outpatient use and costs among patients newly diagnosed with aller-
gic rhinitis (AR). METHODS: This was a 12-year (6/1997-7/2009) retrospective
matched cohort study in United States (U.S.) Florida Medicaid enrollees with newly
diagnosed AR (1 year preceding initial AR diagnosis without any claim for ICD-9
477.0, 477.8, 477.9). Selected were patients receiving 1 INS fill after their initial AR
diagnosis with sufficient data (1 year of data before and 3 years of data after
index INS fill) for analysis. “Adequate” adherence was defined as an INS medication
possession ratio (MPR; calculated as the total days of supply during 18 months)
70% following patient’s index INS fill, and inadequate adherence as MPR 70%.
Patients with adequate INS adherence (Adequate-INS) were matched 1:3 to those
with inadequate adherence (Inadequate-INS) on age at initial AR diagnosis; sex;
race/ethnicity; and Charlson Comorbidity Index and comorbid atopic illness
(asthma, atopic dermatitis, and conjunctivitis) 1 year before index INS fill. Wil-
coxon signed-rank tests compared median outpatient use and costs (in U.S. dollars;
USD) between Adequate-INS and Inadequate-INS groups over 18 months.
RESULTS: Among all enrollees (N7,524,231), 75,337 patients aged 12 years were
newly diagnosed with AR. Of these, 343 Adequate-INS patients were matched to
698 Inadequate-INS patients. Demographics and comorbid illness rates did not
significantly differ between groups at baseline. Median 18-month number of out-
patient visits (19.0 versus 25.0, p0.0001) and costs ($1,633 versus $2,552 in USD,
p0.0001) were significantly lower among Adequate-INS versus Inadequate-INS
patients. CONCLUSIONS: Significant differences between adherence groups in
number and costs of outpatient visits were observed over 18 months following INS
initiation among these U.S. patients receiving State Medicaid Health care coverage.
Results suggest that INS adherence may play a role in improving health outcomes
of patients with AR.
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OBJECTIVES: To develop a comprehensive model to estimate health and cost out-
comes associated with different therapeutic options in major depressive disorder
(MDD), accounting for long-term clinical events and treatment pathways.
METHODS: A discrete event simulation (DES) model was developed with a flexible
time horizon. This model simulated short- and long-term clinical events (partial
response, remission, relapse, recovery, recurrence), adverse events, and treatment
changes (titration, switch, addition, discontinuation) in a cohort of MDD patients.
Patient characteristics influencing clinical evolution were considered (e.g., residual
symptoms). The model was tested using fictitious antidepressants with three lev-
els of efficacy, tolerability and drug cost (low, medium, high) from first-line to
third-line. In the base case analysis, a medium-profile antidepressant was used
first-line, and profiles of subsequent treatment lines depended on reason for
switch (lack of efficacy or low tolerability). Input data were derived from the liter-
ature. Model outputs included time by clinical state, QALYs and costs. Costs were
estimated for the UK, from payer and societal perspectives. One-way sensitivity
analyses were performed. This model will be provided open source so that all
interested researchers can contribute by incorporating new features or adding
input data. RESULTS: Predicted costs and QALYs from this model are within the
range of results from previous economic evaluations. The largest cost components
from payer perspective were physician visits and hospitalisations. Key parameters
driving the predicted costs and QALYs were utility values, effectiveness and fre-
quency of physician visits. Differences in QALYs and costs between two strategies
with different effectiveness increased approximately two-fold when the time ho-
rizon increased from 1 to 5 years. CONCLUSIONS: This DES model can provide a
more comprehensive evaluation of different therapeutic options in MDD, com-
pared to existing Markov models and can be used to compare a wide range of health
care technologies in various groups of MDD patients.
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OBJECTIVES: Markov models developed for cost-effectiveness analysis (CEAs)
often contain differences in model structure due to differences in assumptions.
Such differences may lead to differences in outcome and can therefore impact
decision making. The objective of this analysis was to identify structural as-
sumptions, reported for CEAs comparing the cost-effectiveness of tamoxifen
and anastrazole for adjuvant breast cancer therapy, and to subsequently eval-
uate the impact of these assumptions, both individually as well as combined, on
analysis outcome measures. METHODS: Based on a literature review of available
published Markov model based CEAs comparing tamoxifen and anastrazole, struc-
tural model assumptions were identified. Subsequently, a base case model was
defined and built in R, representing the fundamental structure present in all iden-
tified CEAs from literature. Subsequently, different structural model components
as identified from the published CEAs, were added to the base case model sepa-
rately, as well as simultaneously. Outcome measures Life Years gained (LYG) and
incremental costs were calculated for each of these models. RESULTS: The base
case model outcome demonstrated a gain of 0.263 LYG for anastrazole compared to
tamoxifen with an ICER of €13.868/LYG. The separate impact of assumptions on
LYG, ranged from 0.207 to 0.356, while ICERs ranged from €9804/LYG to €17.966/
LYG. For the comparison of combined assumptions as present in identified CEA’s,
LYs gained ranged even from 0.207 to 0.383 with ICERs ranging from €9683/LYG to
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